Nouveau Life Pharmaceuticals Inc (NOUV)

[cars3]

Read all of this. You will like what they are saying.

NOUV – Cannabis Cultivation Business & Joint Venture

US Cannabis Health is a joint venture involving Puration, Inc., Kali, Inc., and Nouveau Life Pharmaceuticals, Inc. US Cannabis Health was formed for the development of cannabis pharmaceutical and wellness products. The cannabis pharmaceuticals market is forecasted to reach a $50 billion sales by 2029.

December 21, 2018
Kali-Extracts and Nouveau Announce Cannabis Extraction Partnership For Canadian Recreational Marijuana Market
DALLAS, TX - December 21, 2018 -- InvestorsHub NewsWire -- Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced plans with Nouveau Life Pharmaceuticals (USOTC: NOUV) to use KALY’s patented cannabis extraction process in Canada. NOUV has a cannabis cultivation business with operations in the U.S. and Canada. The two companies will work together to produce cannabis extracts utilizing KALY’s patented cannabis extraction process for the recreational marijuana market.

KALY currently produces pharmaceutical grade cannabis extracts that have been involved in multiple clinical trials in addition to utilizing its patented cannabis extraction process in the production of CBD infused nutrition and wellness products to include its own Hemp4mula and CBD infused waters produced by Puration, Inc. (USOTC: PURA) (“PURA”).

KALY is partners with PURA and NOUV in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).

December 20, 2018
The Joint Venture (JV) partnership with KALY and NOUV is proceeding even better than anticipated.
PURA recently spun-off its cannabis cultivation operation with facilities in the U.S. and Canada to NOUV. In conjunction with the spin-off, a portion of the consideration that PURA received from NOUV was slated to be converted into common stock and that NOUV common stock was to be issued to shareholders of PURA. Specifically, PURA sold its cannabis cultivation business to NOUV in exchange for a $1.2 million convertible note with a commitment that the note would promptly be converted to common shares of NOUV and that those converted shares would be distributed in a stock dividend to the shareholders of PURA. PURA and NOUV originally planned to wait for NOUV to execute a reverse spilt before executing the dividend distribution. While pursuing that objective, it became clear the execution of the reverse split would take some time. As NOUV updates its filings and executes on its business plan with the new cannabis cultivation operation, optimistically, a reverse split of NOUV might not be necessary. So, PURA and NOUV management have explored alternative options. In light of the fact that the common shares of NOUV issued to PURA shareholders will not be immediately free trading and will have to season to be free trading under an exemption from registration, PURA and NOUV have resolved to issue a dividend of preferred shares convertible into common shares. In this way, a dividend of equity can be rapidly issued and the seasoning of shares for exemption can begin. If a NOUV reverse proceeds as originally planned, then shareholders will receive the original allocation of 1 common share for every 5 shares of PURA. If a reverse proves unnecessary, then the conversion of preferred shares into common shares will be adjusted accordingly to affect an equal dividend allocation.
Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) and Nouveau Life Pharmaceuticals, Inc. (dba/Nouveau, Inc) (USOTC: NOUV) (“NOUV”) today announced an agreement to expand NOUV’s current cultivation operations to include 100 adjacent acres dedicated to growing hemp under the new Farm Bill legalizing hemp farming and anticipated to be signed into law later today by President Trump. KALY will construct a CBD extraction facility on site based on KALY’s patented extraction process. In addition to the outdoor hemp cultivation, NOUV will build a state-of-the-art greenhouse operation intended for the development of a proprietary hemp cultivar.

NOUV has a cannabis cultivation operation with facilities in the U.S. and Canada. NOUV’s objective in the partnership announced today with KALY is to develop a proprietary pharmaceutical grade hemp cultivar in addition to being a source of hemp supply for a myriad of industries in what management anticipates to be exploding demand in 2019.

KALY, NOUV and PURA are partners in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
Week of November 5th, 2018
NOUV, PURA, KALY, NCM meeting in Dallas.
Kali and NCM are meeting this week in Dallas to both consummate the acquisition and strategize with Puration, Inc. (PURA) and Nouveau Life Pharmaceuticals, Inc. on the recent formation of a joint venture (JV) company to develop cannabis pharmaceutical products. Kali has partnered with PURA and NOUV to form US Cannabis Health, a JV company formed for the development of cannabis pharmaceutical and wellness products. The cannabis pharmaceuticals market is forecasted to reach a $50 billion sales by 2029.
"Representatives of the three companies plan to meet next week in Dallas, Texas at Puration’s headquarters. Look for more news on the JV following next week’s meetings."
https://finance.yahoo.com/news/kali-inc-announces-us-cannabis-155428738.html

November 02, 2018
SARASOTA, Fla., Nov. 02, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali, Inc. (USOTC: KALY) today published the online presentation included here below to detail the strategy behind the recently announced plans with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) to form a joint venture (JV) company to develop cannabis pharmaceutical products. The cannabis pharmaceutical market is anticipated to reach a value of $50 billion by 2029. Nouveau has recently acquired a cannabis cultivation operation from Puration. In the JV, Nouveau would be tasked with developing a proprietary pharmaceutical grade hemp cultivar. The acquired cannabis cultivation has already initiated efforts toward developing a proprietary, pharmaceutical grade hemp cultivar.
https://finance.yahoo.com/news/kali-inc-announces-us-cannabis-155428738.html

October 29, 2018
"Kali, Inc. (USOTC: KALY) today announced entering into discussions with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) to explore forming a joint venture company between the three to develop cannabis pharmaceutical products...Look for more info on Kali’s plans with NCM Biotech and Puration and Nouveau later this week in a management presentation on the company’s comprehensive post acquisition business plan."
https://finance.yahoo.com/news/kali-inc-enters-discussions-puration-150149527.html

October 4, 2018
"In addition to PURA's plan to file its 2018 Q3 report on or before November 12th, NOUV management plans to bring NOUV current with its reporting requirements in the same time frame."
https://finance.yahoo.com/news/puration-inc-targets-november-15th-125000284.html

NOUV remains to be the backbone to this joint venture. Before any products can be extracted or made, the cannabis must be cultivated. NOUV is in a very, very good position.

“Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical products and candidate products.”
https://finance.yahoo.com/news/kali-inc-present-strategy-entering-133802344.html

If this Joint Venture can produce products with greater efficacy than GW Pharmaceutical, the future is very promising for the three companies involved. GW Pharmaceutical is trading on the NASDAQ (NASDAQ:GWPH). Currently it has attracted attention from big companies such as Constellation Brands, Coca-Cola, Heineken, and others. These are only beverage brands, soon it will attract major top tier pharmaceutical companies as well.

"To streamline and concentrate all its resources on the production of cannabis infused beverages, Puration has recently spun-off its cannabis cultivation operation. The spinoff was affected through the execution of a securities exchange agreement with Nouveau Life Pharmaceuticals, Inc., (NOUV) (“NOUV”). Now that the securities exchange agreement between NOUV and Puration is finalized, NOUV is working to rapidly come current with its financial reports. The first steps leading to the stock dividend distribution are underway, and the combined management teams are committed."
https://www.purationinc.com/cannabisbeveragebusinessplan/

"The company acquired First Choice Nursery last year to establish a 25-greenhouse operation in the first step of a plan to grow the operation to 400 greenhouses. First Choice Nursery began booking its first sales in the first quarter of this year.

First Choice Nursery which has an existing twenty-five greenhouse facility in Texas. The company has the opportunity to expand to an additional 400 irrigated greenhouse pads ready for buildout. Renovations have already begun. Puration has a U.S. Patented Cannabis Extraction process licensed from NCM Biotech. The license of the process to Puration is the first and only license NCM Biotech has executed. R&D with NCM Biotech's patented process has demonstrated a high potential for bringing FDA approved pharmaceutical products to market for the treatment of multiple neurological disorders and cancer.

"I have received doctor feedback from more than one of our research initiatives that extracts coming from NCM Biotech's patented process are superior in purity and quality to any other available cannabis extracts," said Frederick Ferri, CEO and Founder of NCM Biotech. "Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical products and candidate products."

Puration and NCM Biotech plan to expand existing University Research relationships to include a portion of the greenhouse facility being utilized to develop a proprietary strain of CBD. Puration will use proceeds from the balance of the traditional nursery operation to expand the operation into its full 400 greenhouse potential. The operation is located in a region of East Texas well known for nursery operations. Texas has recently legalized medical marijuana and is pending the issuance of its first licenses. Puration intends to transition to marijuana growing overtime in conjunction with the legalization process. In the meantime, Puration anticipates the traditional nursery operations have the potential to expand to as high as $16 million in annual sales. Medical Marijuana sales can be substantially higher."

A major component of having the best cannabis extract is having the best cannabis plants from which to extract cannabinoids. Cannabis cultivation is a natural extension of Puration's long-term development. Being headquartered in Texas, it made sense to take advantage of new medical marijuana laws in Texas. Accordingly, Puration acquired an older conventional nursery operation, First Choice Nursery, and immediately began renovations. Puration is now utilizing the 25-greenhouse facility conventionally and anticipates growing to $1 million in annual sales from conventional nursery operations. First Choice Nursery started booking its first sales since the Puration acquisition in the first quarter of this year. Puration has an option on acquiring another 400 greenhouse pads. Puration is working to secure a medical marijuana cultivation license in Texas with future plans to migrate the conventional nursery operation into a cannabis cultivation operation.
https://finance.yahoo.com/news/puration-cannabis-cultivation-business-takes-131300744.html

Puration's Cannabis Cultivation Foundation
Puration has implemented a long-term cannabis cultivation strategy to navigate the evolving legal environment and ultimately establish a recognized brand name in the cannabis marketplace. Through last year's acquisition of First Choice Nursery, Puration has already set up a 25-greenhouse operation in its home state of Texas where limited medical marijuana legalization has passed. The company is working to establish a university-backed cannabis cultivation research facility within the 25-greenhouse operation. In the meantime, the facility is financed by growing conventional household and landscape plants. It is expected to generate $1 million in revenue this year and self-finance the expansion of the 25-greenhouse operation into as many as 400-greenhouses. Once recreational marijuana is legal either through state or federal law, the Texas facility will be in a leadership position with a robust production facility ready-to-go and a university research backed cultivation process in place.

Canadian Cannabis Farmers Co-Op Business Plan
The acquisition of Canadian Cannabis Farmers Co-Op positions Puration for the estimated $5 billion recreational marijuana market expected to be legalized nationwide in Canada this summer. With the acquisition, Puration now has in-house cultivation experience garnered from the operation of a licensed medical marijuana facility of substantial size. The company plans to apply for a recreational license and anticipates its medical marijuana experience to be of benefit in the recreational license application process. Similar to other Canadian marijuana sector companies such as Canopy Growth Corp. (TWMJF), Aurora Cannabis (ACBFF), Aphria (APHQF), MedReleaf (MEDFF), and OrganiGram Holdings (ORGMF). Puration has plans to build substantial in-house operations. The company has already received interest from investors in backing the construction of facilities for pursuing the Canadian legal marijuana market. However, in addition to building out in-house operations, Puration plans to take its acquired expertise to what it expects to be a robust micro-cultivation and micro-processing market. Health Canada recently announced plans to introduce new micro-cultivation and micro-processing licenses. A micro-cultivation license would be issued to an authorized plant canopy area of less than 200 square meters (2,153 square feet), and a micro-processing license allowed for those processing less than 600 kilograms, or 1,323 pounds, of dried cannabis a year. The legalization of recreational marijuana in Canada also includes individual cultivation for up to four plants. Puration plans to serve the micro-cultivation, micro-processing and home-growers marketplace with products and services necessary for production. By establishing a recognized brand name in cannabis cultivation from its in-house production, Puration expects to leverage its brand name to tap into the more profitable micro-cultivation, micro-processing and home-growers marketplace. To help illustrate the opportunity, consider the micro-brewery and home brewing marketplace in the United States alone. Retail dollar sales for craft micro-brewed beer in the U.S. is approximately $26.0 billion, accounting for more than 23% of the overall $111.4 billion U.S. beer market.
https://finance.yahoo.com/news/puration-presents-cannabis-cultivation-strategy-150000832.html

“Puration had initiated a project to expand its extraction process upstream into cannabis cultivation. Having the best extracts depends not only on the extraction process itself, but also on the quality of the cannabis being extracted. Puration has cultivation operations in the United States and Canada.”
https://www.purationinc.com/extraction

Puration Inc Targets November 15th to Declare 1:5 Cannabis Cultivation Stock Dividend
Kali Inc. Enters Discussions with Puration and Nouveau Life Pharmaceuticals to Enter $50 Billion Cannabis Pharmaceuticals Market

NOUV - Important Notes
"Now that the securities exchange agreement between NOUV and Puration is finalized, NOUV is working to rapidly come current with its financial reports." - https://www.purationinc.com/cannabisbeveragebusinessplan/

"NOUV management plans to bring NOUV current with its reporting requirements in the same time frame...on or before November 12th"
https://finance.yahoo.com/news/puration-inc-targets-november-15th-125000284.html

"Management has shown no interest in reverse splits"
Nouveau Life Pharmaceuticals (USOTC: NOUV) ($0.0003) - NOUV has recently acquired a cannabis cultivation operation from cannabis industry juggernaut Puration, Inc. (USOTC: PURA). The company is issuing a stock dividend to the shareholders of PURA. The dividend, set to be declared on the 15th of November, and the overall business relationship with PURA stands to potentially drive NOUV into the double digits between now and the 15th of November...Management has shown no interest in reverse splits and seems content with working in the sub penny range continuing to incubate new cannabis sector enterprises and giving shareholders the opportunity to enjoy one triple zero to double zero run after another.
https://ih.advfn.com/p.php?pid=nmona&article=78569240